Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab. — ON TRAX  

Unresectable Stage III NSCLC Clinical Trial

Official title: Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab

Status Terminated

Clinical Trial Summary

A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.

Clinical Trial Description

Patients undergoing post-CRT treatment for lung cancer with consolidation durvalumab can experience pulmonary AEs that could become severe if not recognized and treated in time.

Data collected will be used to evaluate the likelihood of early detection of pulmonary AEs in unresectable Stage III NSCLC patients on durvalumab. This project seeks to understand if multiparametric mobile technology collecting patient reported outcomes, vital signs, and respiratory function, integrate well into a patients daily life and aid physicians in early detection of pulmonary AEs. ;

Related Conditions & MeSH terms

• Pneumonia
• Unresectable Stage III NSCLC

• NCT number: NCT04381494
• Study type: Interventional
• Source: AstraZeneca
• Status: Terminated
• Phase: Phase 4
• Start date: April 27, 2020
• Completion date: January 27, 2022